Peptichemio: A new oncolytic drug in combination with vincristine and prednisolone in the treatment of non-hodgkin lymphomas

A. M. Carella, A. Bacigalupo, G. Santini, D. Giordano, E. E. Damasio, F. A. Fusco, E. Rossi, A. M. Marmont

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Peptichemio, a new oncolytic drug with alkylating and antimetabolic properties was employed in combination with vincristine and 6-methylprednisolone (PVP) for the treatment of diffuse non-Hodgkin’s lymphomas (NHL), stages III and IV. 52 of 66 patients who entered the PVP protocol were considered evaluable: the overall remission rate in diffuse lymphocytic poorly differentiated lymphomas (DLPD) was 56.6 and 55% in diffuse histiocytic lymphomas (DHL). Median duration of complete remission was 16 months in DLPD and 13 months in DHL. Dramatic results were obtained in ‘oncologic emergencies’, such as mediastinal involvement and spinal cord compression. Bone marrow depression from PVP was moderate and never caused discontinuation of therapy. According to these results the PVP protocol would appear susceptible of offering a major contribution to the chemotherapy of diffuse NHL.

Original languageEnglish
Pages (from-to)211-224
Number of pages14
JournalActa Haematologica
Volume57
Issue number4
DOIs
Publication statusPublished - 1977

Fingerprint

Peptichemio
Vincristine
Drug Combinations
Prednisolone
Non-Hodgkin's Lymphoma
Mantle-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Spinal Cord Compression
Methylprednisolone
Therapeutics
Emergencies
Bone Marrow
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Chemotherapy
  • Malignant lymphomas
  • Non-Hodgkin lymphomas
  • Peptichemio
  • PVP

ASJC Scopus subject areas

  • Hematology

Cite this

Peptichemio : A new oncolytic drug in combination with vincristine and prednisolone in the treatment of non-hodgkin lymphomas. / Carella, A. M.; Bacigalupo, A.; Santini, G.; Giordano, D.; Damasio, E. E.; Fusco, F. A.; Rossi, E.; Marmont, A. M.

In: Acta Haematologica, Vol. 57, No. 4, 1977, p. 211-224.

Research output: Contribution to journalArticle

Carella, AM, Bacigalupo, A, Santini, G, Giordano, D, Damasio, EE, Fusco, FA, Rossi, E & Marmont, AM 1977, 'Peptichemio: A new oncolytic drug in combination with vincristine and prednisolone in the treatment of non-hodgkin lymphomas', Acta Haematologica, vol. 57, no. 4, pp. 211-224. https://doi.org/10.1159/000207884
Carella, A. M. ; Bacigalupo, A. ; Santini, G. ; Giordano, D. ; Damasio, E. E. ; Fusco, F. A. ; Rossi, E. ; Marmont, A. M. / Peptichemio : A new oncolytic drug in combination with vincristine and prednisolone in the treatment of non-hodgkin lymphomas. In: Acta Haematologica. 1977 ; Vol. 57, No. 4. pp. 211-224.
@article{1f4a95390dbb45839003f9df2edf2085,
title = "Peptichemio: A new oncolytic drug in combination with vincristine and prednisolone in the treatment of non-hodgkin lymphomas",
abstract = "Peptichemio, a new oncolytic drug with alkylating and antimetabolic properties was employed in combination with vincristine and 6-methylprednisolone (PVP) for the treatment of diffuse non-Hodgkin’s lymphomas (NHL), stages III and IV. 52 of 66 patients who entered the PVP protocol were considered evaluable: the overall remission rate in diffuse lymphocytic poorly differentiated lymphomas (DLPD) was 56.6 and 55{\%} in diffuse histiocytic lymphomas (DHL). Median duration of complete remission was 16 months in DLPD and 13 months in DHL. Dramatic results were obtained in ‘oncologic emergencies’, such as mediastinal involvement and spinal cord compression. Bone marrow depression from PVP was moderate and never caused discontinuation of therapy. According to these results the PVP protocol would appear susceptible of offering a major contribution to the chemotherapy of diffuse NHL.",
keywords = "Chemotherapy, Malignant lymphomas, Non-Hodgkin lymphomas, Peptichemio, PVP",
author = "Carella, {A. M.} and A. Bacigalupo and G. Santini and D. Giordano and Damasio, {E. E.} and Fusco, {F. A.} and E. Rossi and Marmont, {A. M.}",
year = "1977",
doi = "10.1159/000207884",
language = "English",
volume = "57",
pages = "211--224",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Peptichemio

T2 - A new oncolytic drug in combination with vincristine and prednisolone in the treatment of non-hodgkin lymphomas

AU - Carella, A. M.

AU - Bacigalupo, A.

AU - Santini, G.

AU - Giordano, D.

AU - Damasio, E. E.

AU - Fusco, F. A.

AU - Rossi, E.

AU - Marmont, A. M.

PY - 1977

Y1 - 1977

N2 - Peptichemio, a new oncolytic drug with alkylating and antimetabolic properties was employed in combination with vincristine and 6-methylprednisolone (PVP) for the treatment of diffuse non-Hodgkin’s lymphomas (NHL), stages III and IV. 52 of 66 patients who entered the PVP protocol were considered evaluable: the overall remission rate in diffuse lymphocytic poorly differentiated lymphomas (DLPD) was 56.6 and 55% in diffuse histiocytic lymphomas (DHL). Median duration of complete remission was 16 months in DLPD and 13 months in DHL. Dramatic results were obtained in ‘oncologic emergencies’, such as mediastinal involvement and spinal cord compression. Bone marrow depression from PVP was moderate and never caused discontinuation of therapy. According to these results the PVP protocol would appear susceptible of offering a major contribution to the chemotherapy of diffuse NHL.

AB - Peptichemio, a new oncolytic drug with alkylating and antimetabolic properties was employed in combination with vincristine and 6-methylprednisolone (PVP) for the treatment of diffuse non-Hodgkin’s lymphomas (NHL), stages III and IV. 52 of 66 patients who entered the PVP protocol were considered evaluable: the overall remission rate in diffuse lymphocytic poorly differentiated lymphomas (DLPD) was 56.6 and 55% in diffuse histiocytic lymphomas (DHL). Median duration of complete remission was 16 months in DLPD and 13 months in DHL. Dramatic results were obtained in ‘oncologic emergencies’, such as mediastinal involvement and spinal cord compression. Bone marrow depression from PVP was moderate and never caused discontinuation of therapy. According to these results the PVP protocol would appear susceptible of offering a major contribution to the chemotherapy of diffuse NHL.

KW - Chemotherapy

KW - Malignant lymphomas

KW - Non-Hodgkin lymphomas

KW - Peptichemio

KW - PVP

UR - http://www.scopus.com/inward/record.url?scp=0017324311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017324311&partnerID=8YFLogxK

U2 - 10.1159/000207884

DO - 10.1159/000207884

M3 - Article

C2 - 403727

AN - SCOPUS:0017324311

VL - 57

SP - 211

EP - 224

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - 4

ER -